SFAM
NBIX icon

Springhill Fund Asset Management’s Neurocrine Biosciences NBIX Stock Holding History

Springhill Fund Asset Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-13,612
Closed -$1.51M – 10
2025
Q1 		$1.51M Buy
+13,612
New +$1.72M 7.21% 5

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Springhill Fund Asset Management's NBIX Position: Q2 2025 in Review

Springhill Fund Asset Management sold out of Neurocrine Biosciences (NBIX) in Q2 2025, closing a stake of 13,612 shares — an estimated $1.51M sold.

Springhill Fund Asset Management first reported a position in NBIX in Q1 2025 and held it in 1 quarter. The position peaked at $1.51M in Q1 2025. 585 funds tracked by Wall St. Rank hold NBIX as of Q2 2025.

  • Springhill Fund Asset Management reported no remaining Neurocrine Biosciences position as of Q2 2025 after selling out during the quarter.
  • Springhill Fund Asset Management sold 13,612 Neurocrine Biosciences shares in Q2 2025, an estimated $1.51M.
  • Springhill Fund Asset Management first reported a position in Neurocrine Biosciences in Q1 2025 and held it in 1 quarter.
  • Springhill Fund Asset Management's Neurocrine Biosciences position peaked at $1.51M in Q1 2025.
  • 585 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2025.

Based on Springhill Fund Asset Management's 13F filing for Q2 2025.